Research on CRISPR/Cas9 for Duchenne Muscular Dystrophy
Understanding Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by the progressive degeneration of heart and skeletal muscles. This condition arises from various genetic mutations, including significant deletions, duplications, or minor sequence alterations within the dystrophin gene. Patients with these mutations are unable to produce dystrophin, a critical protein that maintains muscle cell integrity. The absence of dystrophin disrupts proper cell linkage, leading to muscle deterioration.
Prevalence and Symptoms of DMD
Duchenne muscular dystrophy predominantly affects males, with a prevalence rate of 1 in 5,000. The disease manifests through numerous debilitating symptoms such as muscle weakness, respiratory difficulties, and the weakening and enlargement of the heart.
CRISPR/Cas9: A Promising Genome-Editing Tool
Researchers are exploring the potential of CRISPR/Cas9, a revolutionary genome-editing technique, to rectify the genetic mutations associated with DMD. Originally part of the bacterial immune system, CRISPR/Cas9 has been adapted for use in editing other genomes. This system employs “guide RNA” to precisely cut DNA at designated sites, enabling the replacement of defective genes with functional ones.
Recent Advances in Genome Editing
A collaborative study conducted by American and German scientists aimed to address various mutation types linked to Duchenne muscular dystrophy. Their findings, published in Science Advances, detail the identification of 12 optimal guide RNAs targeted at critical regions of DNA responsible for the mutations that cause DMD.
Using stem cells and mice models, the researchers developed three distinct cell lines that represented different types of DMD mutations, including those involving large deletions and duplications. The optimized CRISPR/Cas9 system was successfully employed to correct these mutations in numerous cells.
Impact on Muscle Function
Significantly, the researchers discovered that muscle function could be restored to normal or near-normal levels if 30-50% of the affected cells were corrected. This promising outcome provides hope for patients suffering from Duchenne muscular dystrophy.
Future Directions and Clinical Trials
Encouragingly, human clinical trials have received approvals in both China and the United States. Nevertheless, further research is essential to ensure that these genome edits do not inadvertently cause mutations outside the intended target areas.
Reference
Long C et al. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. 2018. Science Advances, 4: eaap9004.